A Prospective Study of EUS Guided Celiac Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

127 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-06-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for clinical reasons.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Celiac Plexus Block for Chronic Pancreatitis RCT

NCT02399800

Pancreatitis, Chronic Pancreatitis

TERMINATED NA

Pediatric Longitudinal Cohort Study of Chronic Pancreatitis

NCT03672422

Pancreatitis, Chronic Pancreatitis, Acute

COMPLETED

Modulation of Secondary Bile Acids Through the Intestinal Microbiota After Consumption of a High-protein Diet.

NCT05906641

Healthy

COMPLETED NA

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

NCT05664880

Chronic Pancreatitis

RECRUITING EARLY_PHASE1

Malnutrition in Chronic Pancreatitis, Trans-sectoral Study

NCT04476056

Chronic Pancreatitis Malnutrition Sarcopenia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pancreatitis Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

subjects who are getting a celiac block for chronic pancreatitis

triamcinolone

Intervention Type DRUG

80mg of triamcinolone injected into the celiac ganglion during the EUS-CB

2

subjects who are getting a celiac block for pancreatic cancer

98% dehydrated alcohol

Intervention Type DRUG

10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

triamcinolone

80mg of triamcinolone injected into the celiac ganglion during the EUS-CB

Intervention Type DRUG

98% dehydrated alcohol

10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Kenalog 80mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic abdominal pain from documented chronic pancreatitis or pancreatic cancer or other visceral malignancy that are undergoing EUS-guided CB (for purposes other than this study) will be eligible to participate in this study.
* Patients with chronic pancreatitis and pancreatic cancer must have documented disease by CT, ERCP, or EUS.
* No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.
* Patient must provide signed written informed consent